Age |
|
Median (IQR) Range | 56 (50 - 66) 27 - 80 |
ECOG |
|
0 1 2 | 1 (1.2%) 73 (84.9%) 12 (14.0%) |
Gender |
|
Male female | 75 (87.2%) 11 (12.8%) |
Site |
|
Larynx Hypopharynx | 77 (89.5%) 9 (10.5%) |
Grade |
|
1 2 3 | 14 (16.3%) 61 (70.9%) 11 (12.8%) |
Tumor T-stage |
|
1 2 3 4 | 11 (12.8%) 26 (30.2%) 33 (38.4%) 16 (18.6%) |
Nodal N-stage |
|
0 1 2 3 | 51 (59.3%) 5 (5.8%) 26 (30.2%) 4 (4.7%) |
AJCC stage |
|
1 2 3 4 | 11 (12.8%) 16 (18.6%) 17 (19.8%) 42 (48.8%) |
Pretreatment hemoglobin (g/dl) |
|
Median (IQR) <13 (male) >13 (male) <12 (female) >12 (female) | 13.1 (11.9 - 14.2) 31 (41.3%) 44 (58.7%) 4 (36.4%) 7 (63.6%) |
Median follow-up duration | 9.33 (4.2 - 17.7) |